These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 9296101

  • 1. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J, Montes B, Delmas B, Vendrell JP, Janbon F, Segondy M.
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [Abstract] [Full Text] [Related]

  • 2. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.
    Antivir Ther; 1999 May; 4(4):195-202. PubMed ID: 10723498
    [Abstract] [Full Text] [Related]

  • 3. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 May; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 May; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 5. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [Abstract] [Full Text] [Related]

  • 6. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Dec; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 8. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Aug; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 9. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [Abstract] [Full Text] [Related]

  • 10. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A, Peraire J, Arnó A, Gutiérrez C, Cervantes M, Colomer J, Villalonga C, Camafort M, Ruiz L, Balaguer M, Vidal F, Richart C, Clotet B.
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 12. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC, Pottage JC, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L.
    Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
    [Abstract] [Full Text] [Related]

  • 13. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, Cort S, Sullivan JL.
    N Engl J Med; 1997 May 08; 336(19):1343-9. PubMed ID: 9134874
    [Abstract] [Full Text] [Related]

  • 14. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 08; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Nov 08; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 16. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Nov 08; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 17. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P, Principi N, Gabiano C, Galli L, Gattinara GC, Caselli D, Zuccotti G, La Regina A, Paga C.
    Antivir Ther; 1997 Jan 08; 2(1):47-55. PubMed ID: 11322266
    [Abstract] [Full Text] [Related]

  • 18. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 08; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 19. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.
    Int J STD AIDS; 2003 May 08; 14(5):350-5. PubMed ID: 12803944
    [Abstract] [Full Text] [Related]

  • 20. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.